ESGAR Rectal Imaging Guideline Group, Monique Maas
4 min
As the rectal cancer treatment landscape evolves toward organ-preserving strategies and total neoadjuvant therapy, accurate imaging for restaging becomes critically important. The European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Rectal Imaging Guideline Group sought to update their 2018 consensus recommendations. Utilizing an adapted RAND-UCLA Appropriateness Method, a panel of 26 international abdominal imaging experts evaluated 126 clinical items. The process involved two online voting rounds and comprehensive literature reviews to establish modern standards for hardware, patient preparation, image acquisition, interpretation criteria, and structured reporting for rectal cancer restaging.
The expert panel achieved consensus on 121 out of 126 items (96%), with near-universal agreement on restaging specifics (98% agreement across restaging items). Among the major updates is the recommendation for a preparatory micro-enema before restaging MRI to minimize susceptibility artifacts on diffusion-weighted imaging (DWI). Furthermore, the guidelines establish a response-based classification system for organ preservation, prompting radiologists to categorize patients into (near-)complete response, minor residual tumour, or major residual tumour. For suspected complete or near-complete responses, the panel advises against assigning a specific ycT-category because it is unreliable and lacks clinical utility. Instead, reports should combine T2-weighted MRI, DWI, and endoscopy findings.
The updated recommendations refine how clinicians evaluate specific pathological features after treatment. For instance, the guidelines clarify that a normalized two-layered rectal wall or homogeneous hypointense fibrotic residue on T2W MRI suggests a complete response, while cautioning that apparent tumour regression often lags behind true histological response. The panel noted that traditional MRI tumour regression grading (mrTRG) is useful for distinguishing good versus poor overall response but lacks the sensitivity to identify complete responders independently. Specific guidance is also provided for assessing mesorectal fascia involvement (ycMRF), extramural venous invasion (ycEMVI), and nodal restaging (ycN-category) using short-axis thresholds and monitoring growth over time.
OBJECTIVES: To provide up-to-date consensus recommendations on the acquisition, interpretation and reporting of MRI for restaging and response evaluation of rectal cancer after neoadjuvant treatment. MATERIALS AND METHODS: A panel of twenty-six abdominal imaging experts from the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) participated in an online consensus process, led by three independent non-voting chairs. The process adhered to an adapted version of the RAND-UCLA Appropriateness Method. A total of 126 items were scored (22 general, 55 on primary staging, and 49 on restaging after neoadjuvant treatment), and classified using a cut-off of ≥ 80% to establish consensus. RESULTS: Consensus was reached for 121 items (96%), from which recommendations regarding hardware, patient preparation, image acquisition protocols, criteria for image interpretation, and MRI reporting were constructed. The current manuscript addresses the results related to restaging after neoadjuvant treatment. Only 1/49 restaging items did not reach consensus. Compared to the previous guideline editions, updated and more detailed recommendations were established on how to assess fibrosis after neoadjuvant therapy, how to restage in the setting of organ preservation, the use of tumour regression grading systems, response assessment in mucinous tumours, evaluation of mesorectal fascia (MRF) involvement and presence of extramural venous invasion (EMVI) after neoadjuvant treatment, and how to deal with nodal response for defining the ycN-category after treatment. CONCLUSIONS: These updated expert consensus recommendations serve as clinical guidelines for the restaging of rectal cancer after neoadjuvant treatment using MRI. Recommendations for primary staging are addressed in a separate publication. KEY POINTS: QuestionSince the last ESGAR rectal imaging guideline update, the rectal cancer treatment landscape has further evolved, necessitating updates to the existing guidelines. FindingsAn online consensus process involving 26 panellists led to 96% consensus across 121 items discussed, including 49 items related to restaging after neoadjuvant treatment. Clinical relevanceKey updates included in these updated guidelines for MRI restaging of rectal cancer include new recommendations for assessing fibrosis, identifying patients for organ preservation, use of tumour regression grading systems, assessing mucinous tumours, ycEMVI, ycMRF, and ycN assessment.
Sam: What's the guidance when the signal is genuinely ambiguous—sitting between complete and minor?
Alex: Extend the observation window by six to twelve weeks before a second restaging scan. That gives post-treatment inflammation time to resolve, which can shift an ambiguous read into a clearer one. It's a conservative call, but the right one when the alternative is either unnecessary surgery or a missed residual tumor.
Sam: What about extramural vascular invasion? Does restaging change how that's assessed?
Alex: The panel mandates using the same grading system applied at baseline—consistency across timepoints is the principle. And a strong majority of panelists agreed that diffusion-weighted imaging adds value for detecting persistent invasion within fibrotic tissue, where T2 alone can be misleading because fibrosis and residual tumor can look structurally similar.
Sam: Lymph node evaluation is notoriously difficult post-treatment. How does the framework handle that?
Alex: For mesorectal nodes, there's a five-millimeter short-axis threshold, though the panel explicitly flags its limitations—size criteria after treatment are less reliable than at baseline because treatment-related changes alter nodal morphology. The practical guidance is to monitor nodal growth over serial scans, a test-of-time approach rather than a single-point decision. For lateral nodes, no specific size thresholds reached consensus at all.
Sam: So the framework is deliberately pattern-based rather than threshold-driven. That puts a lot of interpretive weight on the radiologist.
Alex: It does, and that's a real limitation. Consensus on a framework doesn't automatically translate to inter-reader reliability in practice. The guidelines standardize what to look for, but how consistently different radiologists apply those criteria in ambiguous cases is a separate empirical question the paper doesn't resolve.
Sam: On the process itself—were there any procedural gaps worth flagging?
Alex: Two of the twenty-six panelists didn't complete the first questionnaire, so round one ran on twenty-four responses. The authors are transparent about it, and in practice the impact was minimal—second-round agreement was high enough that the one unresolved restaging item was settled during manuscript revision with full panel input. But it's worth noting for anyone scrutinizing the methodology closely.
Sam: Looking forward, the therapeutic landscape is shifting. Total neoadjuvant therapy and targeted radiotherapy boosts are pushing complete response rates higher. Does that create a problem for these criteria?
Alex: It does, and the paper acknowledges it directly. Preliminary experience suggests response patterns vary across neoadjuvant strategies, which means criteria calibrated on one treatment context may not transfer cleanly to another. These guidelines represent the current best consensus, but they'll need updating as the evidence base for newer regimens matures.
Sam: And beyond imaging, the paper points toward integrated diagnostics—serial MRI alongside liquid biopsies, histopathology, genomic profiling. That's a substantial expansion of what restaging means.
Alex: Right. The radiologist's role in this framework is already interpretively demanding, and the trajectory is toward even greater integration with molecular data. Whether that's operationalizable in routine clinical settings—rather than just in specialized centers—is an open question. The guidelines get the imaging piece right. The harder problem is building the multidisciplinary infrastructure to act on what the imaging tells you.
Sam: A well-constructed consensus document, then, with clear clinical utility and honest acknowledgment of where the evidence runs thin.
Alex: Thanks for listening to ResearchPod.